$1.28 EPS Expected for Strayer Education, Inc. (STRA); Myriad Genetics (MYGN) Sentiment Is 0.86

February 21, 2018 - By Marie Mckinney

Analysts expect Strayer Education, Inc. (NASDAQ:STRA) to report $1.28 EPS on March, 2 before the open.They anticipate $0.33 EPS change or 34.74% from last quarter’s $0.95 EPS. STRA’s profit would be $13.70M giving it 17.89 P/E if the $1.28 EPS is correct. After having $0.34 EPS previously, Strayer Education, Inc.’s analysts see 276.47% EPS growth. The stock decreased 1.51% or $1.4 during the last trading session, reaching $91.58. About 46,200 shares traded. Strayer Education, Inc. (NASDAQ:STRA) has risen 93.51% since February 21, 2017 and is uptrending. It has outperformed by 76.81% the S&P500.

Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company has market cap of $2.27 billion. The firm offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It has a 17.46 P/E ratio. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer.

Ratings analysis reveals 0 of Myriad Genetics’s analysts are positive. Out of 2 Wall Street analysts rating Myriad Genetics, 0 give it “Buy”, 2 “Sell” rating, while 0 recommend “Hold”. MYGN was included in 2 notes of analysts from October 10, 2016. Deutsche Bank initiated Myriad Genetics, Inc. (NASDAQ:MYGN) on Wednesday, January 18 with “Sell” rating. Ladenburg Thalmann downgraded the stock to “Sell” rating in Monday, October 10 report.

Since January 1, 0001, it had 0 insider buys, and 8 insider sales for $6.39 million activity.

Analysts await Myriad Genetics, Inc. (NASDAQ:MYGN) to report earnings on May, 1. They expect $0.27 EPS, 0.00% or $0.00 from last year’s $0.27 per share. MYGN’s profit will be $18.86M for 30.14 P/E if the $0.27 EPS becomes a reality. After $0.31 actual EPS reported by Myriad Genetics, Inc. for the previous quarter, Wall Street now forecasts -12.90% negative EPS growth.

The stock decreased 0.79% or $0.26 during the last trading session, reaching $32.55. About 535,127 shares traded. Myriad Genetics, Inc. (MYGN) has declined 37.47% since February 21, 2017 and is downtrending. It has underperformed by 54.17% the S&P500.

Consonance Capital Management Lp holds 7.9% of its portfolio in Myriad Genetics, Inc. for 1.97 million shares. Tieton Capital Management Llc owns 251,143 shares or 7.81% of their US portfolio. Moreover, Camber Capital Management Llc has 4.59% invested in the company for 2.00 million shares. The Pennsylvania-based S&T Bank Pa has invested 3.15% in the stock. Millrace Asset Group Inc., a Pennsylvania-based fund reported 32,738 shares.

Strayer Education, Inc., through its subsidiaries, provides a range of post-secondary education and other academic programs in the United States. The company has market cap of $980.01 million. The firm operates Strayer University that provides undergraduate and graduate degree programs in business administration, accounting, information technology, education, health services administration, nursing, public administration, and criminal justice to working adult students through its 74 physical campuses primarily located in the Mid-Atlantic and Southern regions, as well as through online. It has a 26.23 P/E ratio. It also offers an executive MBA online through its Jack Welch Management Institute.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>